Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial
Journal
Lancet (London, England)
Journal Volume
402
Journal Issue
10399
Date Issued
2023-07-29
Author(s)
Platzbecker, Uwe
Della Porta, Matteo Giovanni
Santini, Valeria
Zeidan, Amer M
Komrokji, Rami S
Shortt, Jake
Valcarcel, David
Jonasova, Anna
Dimicoli-Salazar, Sophie
Tiong, Ing Soo
Li, Jiahui
Zhang, Jennie
Giuseppi, Ana Carolina
Kreitz, Sandra
Pozharskaya, Veronika
Keeperman, Karen L
Rose, Shelonitda
Shetty, Jeevan K
Hayati, Sheida
Vodala, Sadanand
Prebet, Thomas
Degulys, Andrius
Paolini, Stefania
Cluzeau, Thomas
Fenaux, Pierre
Garcia-Manero, Guillermo
Abstract
Erythropoiesis-stimulating agents (ESAs) are the standard-of-care treatment for anaemia in most patients with lower-risk myelodysplastic syndromes but responses are limited and transient. Luspatercept promotes late-stage erythroid maturation and has shown durable clinical efficacy in patients with lower-risk myelodysplastic syndromes. In this study, we report the results of a prespecified interim analysis of luspatercept versus epoetin alfa for the treatment of anaemia due to lower-risk myelodysplastic syndromes in the phase 3 COMMANDS trial.
SDGs
Type
journal article